THE ORAL DEXAMETHASONE EFFECTIVENESS IN REDUCING GASTROINTESTINAL AND NEUROLOGICAL SIDE EFFECTS OF METRIZAMIDE LUMBAR MYELOGRAPHY: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
DOI:
https://doi.org/10.48047/65662z81Keywords:
Dexamethasone, Metrizamide, Lumbar MyelographyAbstract
Background: One of the most popular contrast agents is metrizamide which is also nonionic and the reason behind its high application in lumbar myelography is because of its high diagnostic quality as compared to the older contrast agents such as Pantopaque. But it has a range of side effects, especially gastrointestinal in nature, nausea, vomiting, headaches and others. Previous research has indicated that these side effects can be decreased by steroid treatments. The study was conducted to determine the effectiveness of oral dexamethasone in the management of gastrointestinal and other adverse effects that are prevalent with metrizamide lumbar myelography. Methods: It was a double-blinded placebo-controlled study together with 145 adult patients with either chronic low back and/or leg pain and underwent lumbar metrizamide myelography. At intervals, the participants were randomly grouped into dexamethasone (4 mg) and placebo before and after the procedure. The severity of the symptoms was evaluated by the use of a 24-item symptom checklist prior to the procedure and 24 hours post-procedure. Chi-square tests, correlation coefficients, and post hoc tests were the methods used to analyze the data to determine the relationship between treatment and changes in the symptoms. Results: The findings demonstrated that there was a statistically significant decrease in vomiting symptoms in the dexamethasone group whereby 10.5% patients in the placebo group reported increased vomiting symptoms as compared to 0 in the dexamethasone group ( 2 -test = 4.48, p = 0.034). The difference in other symptoms like headache and nausea was not statistically significant although there was a reduction. Pain in the legs and weakness in legs or feet were also significantly improved in the dexamethasone group, also not significantly. The results of the analysis also indicated a positive relationship between nausea and the scores on MMPI hysteria in the group of dexamethasone. Conclusion: In patients who underwent metrizamide lumbar myelography, oral dexamethasone was effective in the reduction of some gastrointestinal side effects especially vomiting. Even though the drug failed to alleviate all the side effects, its protective effects were specifically noticeable in the elderly patients. Personality traits also were recognized as having an impact on reporting of nausea and other symptoms in the study.
Downloads
References
Johnson AJ, Burrows EH. Thecal deformity after lumbar myelography with iophendylate (Myodil) and meglumine iothalamate (Conray 280). Br J Radiol 1978;51: 196-202.
Kieffer SA, Binet EF, Esquerra JV, Hantman RP, Gross CE. Contrast agents for myelography: clinical and radiological evaluation of Amipaque and Pantopaque. Radiology 1978;129:695-705.
Dugstad G, Eldevik P. Lumbar myelography. Acta Radiol [Suppl] (Stockh) 1977;355:17-30.
Grainger RG, Kendall BE, Wylie IG. Lumbar myelography with metrizamide—a new non-ionic contrast medium. Br J Radiol 1976;49:996-1003.
Gelmers AJ. Adverse side effects of metrizamide in myelography. Neuro-radiology 1979;18: 119-123.
Witwer G, Cacayorin ED, Bernstein AD, Hubballah MY, Yuan HA, Kieffer SA. Iopamidol and metrizamide for myelography: prospective double-blind clinical trial. AJNR 1984;5:403-407, AJR 1984;143:869-873.
Turski PA, Sackett JF, Gentry LR, Strother CM, Matozzi F. Clinical comparison of metrizamide and lopamidol for myelography. AJNR 1983;4:309-311.
Skalpe IO, Amundsen P. Lumbar radiculography with metrizamide. Radiology 1975;115:91-95.
Sortland O, Nestvold K, Kloster R, Aandahl MH. Comparison of iohexol and metrizamide in myelography. Radiology 1984;151:121-122.
Gabrielsen TO, Gebarski SS, Knake JE, Latack JT, Yang PJ, Hoff JT. Iohexol versus metrizamide for lumbar myelography: double-blind trial. AJNR 1984;5:181-183.
Gabrielsen SS, Gabrielsen TO, Knake JE, Latack JT, Hoff JT. Iohexol versus metrizamide for lumbar myelography: preliminary report of double-blind trial. Neurosurgery 1984;14:19-21.
Eldevik OP, Nakken KO, Haughton VM: The effect of dehydration on the side effects of metrizamide myelography. Radiology 1978;129:715-716.
Nickel AR, Salem JJ. Clinical experience in North America with metrizamide. Acta Radiol [Suppl] (Stockh) 1977;355:409-416.
Ahigren P. Amipaque myelography. The side effects.
Bertoni JM, Schwartzman RJ, Van Horn G, Partin J. Asterixis and encephalopathy following metrizamide myelography: investigations into possible mechanisms and review of the literature. Arch Neurol 1981;9:366–370.
Picard J, Espinayini H, Yockell RA. Serious neurological complications of metrizamide myelography. J Neuroradiol 1979;6:3-14.
Masdeu JC, Glitsa GG, Rodriguez FA, Martinez-Lage M, Marve A. Tinnitus and acute axonal polyneuropathy after metrizamide myelography. AJNR 1983;4:200-202.
Daro Transit expressive (nonfluency) aphasia after metrizamide myelography. AJNR 1985;5:945–949.
Kelley PE, Daroff RB, Sheramata WA, McCormick JR. Unusual effects of metrizamide lumbar myelography. Arch Neurol 1980;37:588–589.
Rubin D, Horowitz G, Katz RL. Asterixis following metrizamide lumbar myelography. Arch Neurol 1980;37:52.
Drayer BR, Vassallo C, Sudikovsky A, et al. A double-blind clinical trial of iopamidol versus metrizamide for lumbar myelography: a comparative study. AJNR 1983;5:531–537.
Malinor MD, Houston LW, Strother CM, Turski PA, Sackett JF, Boyer M. Lotrol versus metrizamide in lumbar myelography: a double-blind study. Radiology 1986;158:845-847.
Ekholm SE, Reece K, Coleman JR, Kido DK, Fischer HW. Metrizamide— a potential in vivo inhibitor of glucose metabolism. Radiology 1983;147:119-121.
Bachelard HS. Specificity and kinetic properties of monosaccharide uptake into guinea pig cerebral cortex in vitro. J Neurochem 1971;18:213-222.
Bertoni JM. Metrizamide inhibits human brain hexokinase. Neurology 1982;32: 884-887.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
